Across TCGA pan-cancer cohorts, PPP1R37 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PPP1R37 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher PPP1R37 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP1R37 expression acts as an unfavorable survival marker.
ESCA are the cancer types where PPP1R37 Mutation most reproducibly stratifies survival.